Dr. Zakaria reviewed HIF2α inhibitors in RCC: belzutifan shows strong ORR/PFS; combos improve outcomes; promising roles in frontline and adjuvant settings. Dr. Voss reviewed non-clear cell RCC: diverse biology needs tailored therapy; cabozantinib/ICIs help papillary, less in chromophobe; new targets under study. Dr. Chahoud: STELLAR-0O2 trial—Zanza+nivo showed strong ORR (63%) and PFS (18.5 mo); triplet underperformed; supports further IO combo development. Dr. Tawagi: irAEs common with IO (higher in combos); onset 4–12 wks; manage with monitoring, steroids, and targeted agents like infliximab. The panel discussed on non-clear RCC: NGS testing useful; nephritis management complex; single-arm trials preferred; belzutifan and new targets (NPP3, CA9) under study.